Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis - Research and Markets

Research and Markets
Posted on: 04 Sep 17

The "Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis" report has been added to Research and Markets' offering.

Cardiovascular disease (CVD) is a broad therapy area containing a range of indications relating to the human vasculature, heart and lipid levels. There is considerable first-in-class innovation within the CVD pipeline, comparable with the industry average. The molecular target groups with the highest proportion of first-in-class products include lipid metabolism, transmembrane and extracellular signaling, intracellular signal transduction and ion channels.

Of the four key CVD indications identified in this report (hypertension, heart failure, dyslipidemia and thrombosis), the hypertensive pipeline is the largest, with 238 products in development. The pipelines for heart failure and dyslipidemia are also large. Drugs in development for thrombosis, and specifically the treatment or prevention of thrombosis itself (as opposed to managing the underlying risk factors) has a relatively small pipeline of just 104 products. Overall, there are 1,400 plus products in the CVD pipeline.

There has been vast scientific innovation within the CVD therapeutics market over recent decades, particularly within the anti-dyslipidemia market, first with the introduction of statins such as Lipitor (atorvastatin), and more recently with the introduction of PCSK9 inhibitors. Innovation continues within the dyslipidemia pipeline, The most promising first-in-class development within dyslipidemia focuses on targeting elements of the reverse lipid transport pathway. This is the process of high density lipoproteins (HDL) collecting cholesterol from cells, such as macrophages within atherosclerotic plaques, for removal from circulation in the liver via receptors such as scavenger receptor class B member 1 (SRB1).

Conventional classes of molecular target within the treatment of CVD are now showing relatively low levels of development, as innovation moves towards diverse targets related to the immune system, and transmembrane and extracellular signaling - with transmembrane proteins being a prominent source of innovation within the CVD pipeline.

This report has been designed to identify innovative pipeline programs across a therapy area with a focus on indications with high R&D activity and strong innovation, as well as a competitive commercial landscape and high levels of deal activity. Monitoring innovative new product developments is becoming an increasingly vital part of competitive intelligence for all market participants, and increasingly important for companies seeking strategic partnerships or looking to acquire technologies, products or other companies.

Key Topics Covered:

1 Table of Contents

2 Executive Summary

3 The Case for Innovation

4 Clinical and Commercial Landscape

5 Assessment of Pipeline Product Innovation

6 Signaling Network and Innovation Alignment within Cardiovascular Disease

7 First-in-Class Target and Pipeline Program Evaluation

8 Strategic Consolidations

9 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/g6dklr/frontier_pharma

View source version on businesswire.com: http://www.businesswire.com/news/home/20170904005353/en/

Business Wire
www.businesswire.com

Last updated on: 04/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.